Sciclone Pharma (SCLN) Tops Q1 EPS by 17c

Sciclone Pharma (NASDAQ: SCLN) reported Q1 EPS of $0.31, $0.17 better than the analyst estimate of $0.14. Revenue for the quarter came in at $42.9 million versus the consensus estimate of $39.94 million.

• Revenues: In the first quarter 2017, SciClone reported revenues of $42.9 million, compared to $36.5 million for the same period in 2016.
• GAAP Diluted EPS: In the first quarter 2017, SciClone reported GAAP diluted earnings per share of $0.28, compared to $0.15 for the same period in 2016.
• Non-GAAP Diluted EPS: In the first quarter 2017, SciClone reported non-GAAP diluted earnings per share of $0.31, compared to $0.19 for the same period in 2016.

For earnings history and earnings-related data on Sciclone Pharma (SCLN) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
• AngioDynamics (ANGO) Tops Q1 EPS by 7c, Beats on Revenue; Offers F27 Revenue Guidance
• Mangoceuticals closes $500K offering at 74% premium to recent price